April 25, 2017

To our patients with EpiPens,

On March 31, 2017 the Food and Drug Administration issued a notice regarding a patient-level recall of two different EpiPens. **This recall was issued as a result of the receipt of two previously disclosed reports outside of the United States of failure to activate the device due to a potential defect in a supplier component.**

The potential defect could make the device difficult to activate in an emergency. Both reports are related to the single lot that was previously recalled. The incidence of the defect is extremely rare. Testing and analysis across the potentially impacted lots has not identified ANY units with the defect however, the recall has been expanded to include additional lots as a precautionary measure, out of an abundance of caution.

The affected lots are listed below.

Product Name	NDC #	Affected Lots
EpiPen 2-Pak Auto-Injectors 0.3 mg	49502-0500-02	5GM631 exp. 04/17 5GM640 exp. 05/17 6GM082 exp. 09/17 6GM072 exp. 09/17 6GM081 exp. 09/17 6GM088 exp. 10/17 6GM199 exp. 10/17 6GM091 exp. 10/17 6GM198 exp. 10/17 6GM087 exp. 10/17
EpiPen Jr 2-Pak Auto-Injectors 0.15 mg	49502-0501-02	5GN767 exp. 04/17 5GN773 exp. 04/17 6GN215 exp. 09/17

If you have an affected lot please call:

- Mylan Customer Relations at **1-800-796-9526** or visit **www.Mylan.com/EpiPenRecall**
- FDA Consumer Inquiry line at **1-888-INFO-FDA (1-888-463-6332)** or visit **www.fda.gov**

The risk of a problem is very low but we think it is important for you to have this information as a precautionary measure.

Sincerely Yours,

Seth Franklin, M.D., Milah Frownfelter, M.D., Mitchell Karton, M.D., Robert Kitchell, M.D.